Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Oncotarget | Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas

News

November 17, 2022
PRESS RELEASE: On November 17, 2022, Oncotarget published a new research paper, entitled, “Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.” continue reading »

Biomarkers May Predict Neoadjuvant Chemosensitivity in Bladder Cancer

Oncotarget

November 15, 2022
In a new study, researchers aimed to identify and validate predictive biomarkers of response to neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). continue reading »

Oncotarget | MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

News

November 10, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on November 2, 2022, entitled, “MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.” continue reading »

Oncotarget | Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study

News

November 9, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.” continue reading »

Oncotarget | Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer

News

November 8, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer.” continue reading »